Yiran Zheng, Ph.D.
Professor
Department of Pharmaceutics, Biopharmaceuticals
Email: yrzheng@suda.edu.cn
Biography
Education
2010 - 2015: Massachusetts Institute of Technology (USA), Ph.D.
2006 - 2009: Johns Hopkins University (USA), B.S.
Workexperience
2019 - current: Professor, College of Pharmaceutical Sciences, Soochow University
2017 - 2019: Research Scientist, Institute of Bioengineering and Nanotechnology (IBN), A*STAR, Singapore
2015 - 2017: Postdoctoral fellow, Institute of Bioengineering and Nanotechnology (IBN), A*STAR, Singapore
Research Interests
1. CAR-T therapy, Cancer vaccine, Autoimmune diseases, Biomaterials, Smart drug delivery system
2.Interdisplinaryresearch in immuno-engineering by leveraging on immunology, materials science and biotechnology to create new Chimeric Antigen Receptor T (CAR-T) therapies and cancer vaccines. Technologies have been patented in multiple countries including China, USA, Europe,Japan,andenabledan underogingphase I clinical trial for solidtumorinUSA
Select Publications
1. X. Chen, M. Gao, S. An, L. Zhao, W. Han, W. Wan, J. Chen, S. Ma, W. Cai, Y. Cao, D. Ding, Y. Y. Yang, L. Cheng*, Y. Zheng*. Enhancing adoptive T cell therapy for solidtumorwith cell-surface anchored immune checkpointInhibitornanogels. Nanomedicine: NBM2022, https://doi.org/10.1016/j.nano. 2022.102591.
2. Y. Zheng*, Z. Zhong*. Roadmap to next-generation cancer vaccines. Journal of Controlled Release2022, 347, 308-313, doi:10.1016/j.conrel.2022.05.005.(Cover)
3. M. He, T. Yang, Y. Wang, M. Wang, X. Chen, D. Ding*, Y. Zheng*, H. Chen*. Immune checkpoint inhibitor‐based strategies for synergistic cancer therapy. Advanced Healthcare Materials2021, 10(9): 2002104.
4. Y. Zheng*, J. Kng, C. Yang, J. L. Hedrick, Y. Y. Yang*. Cationic polymer synergizing with chemotherapeutics and re-purposingantibiotics against cancer cells. Biomaterials Science2021, 9, 2174-2182.
5. X. Wang#, Y. Zheng#, C. Bao, G. Zhong, S. Liu, N. Wiradharma, W. Fan, Y. Y. Yang*, X. Wang*, Y. Huang*. Branched helical peptides enhanced antitumor efficacy and selectivity. Biomaterials Science2020, 8, 6387-6394.
6. L. Tang*#, Y. Zheng#, M. Melo, L. Mabardi, A. P. Castano, Y.Q. Xie, N. Li, S. B. Kudchodkar, H. C. Wong, E. K. Jeng, M. V. Maus, and D. Irvine*. Enhancing T-cell therapy through TCR signaling-responsive nanoparticle drug delivery. Nature Biotechnology2018,36 (8), 707. (Cover) Reported as “AbackpackrevsupT-cellactivity” by Shum, Heslop
7. Y. Zheng, L. Tang, L. Mabardi, S. Kumari and D. Irvine*. Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or non-internalizing receptors. ACS Nano2017, 11(3):3089-3100.
8. H. Liu, K. Moynihan, Y. Zheng, G. Szeto, A. Li, B. Huang, D. Egeren, C. Park, D.Irvine*. Structure-based programming of lymph-node targeting in molecular vaccines. Nature2014, 507(7493): 519–522.
9. Y. Zheng, M. T. Stephan, S. A. Gai, W. Abraham, A. Shearer, and D. J. Irvine. In vivoTargetingof adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. Journal of Controlled Release2013, 172(2):426-35.
